PV Bulletin

Tag archive

Guideline

publicMedicines and Healthcare products Regulatory Agency · United Kingdom · Updated Jul 3, 2026

Changes to Labels and Patient Information Leaflets - Self-Certification Process

Urgency: High

MAHs must categorize their proposed label and PIL updates, utilizing the self-certification route for those not requiring full assessment; submissions validated through this route will receive acceptance letters within 14 days.

LabelingRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead, QPPV
verifiedRegulatory action: Guideline
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency · United Kingdom · Updated Jul 3, 2026

Best practice in the labelling and packaging of medicines

Urgency: High

MAHs must update labelling components to meet new criteria, including a minimum font size of 7 points and essential information requirements regarding the medicine's name, strength, route of administration, posology, warnings, and indications as per the guidance. New packaging must be incorporated into stocked products within six months of approval.

LabelingRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead, QPPV
verifiedRegulatory action: Guideline
Read impact briefarrow_forward
publicFDA · USA · Updated Jun 4, 2026

FDA Final Guidance on Postapproval Requirements and Resources for ANDAs

Urgency: Low

Review the guidance to ensure compliance with post-marketing safety reporting timelines and annual report submissions; update SOPs for ICSR processing and periodic report generation.

Country ComplianceICSRRegulatory Intelligence Lead
SOP Impact3 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead, QPPV
verifiedRegulatory action: Guideline
Read impact briefarrow_forward
publicFDA · USA · Updated Jun 5, 2026

FDA Intent to Exempt Certain Unclassified Medical Devices from 510(k) Requirements

Urgency: Low

Identify which unclassified medical devices are affected by the exemption; update regulatory submissions and post-market surveillance plans accordingly; ensure compliance with general controls and post-market surveillance obligations.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceLow
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guideline
Read impact briefarrow_forward

Get updates for your PV role

Subscribe to impact-first pharmacovigilance updates. Select every role you want in your digest.

Digest roles: Regulatory Intelligence Lead. Work email only